The safety, clinical efficacy, and cost-effectiveness of biosimilar infliximab in adult inflammatory bowel disease (IBD) have now been extensively shown. Limited data have been collected in the paediatric setting. We report nationwide, prospective, clinical safety and effectiveness data for patients from all 3 Scottish paediatric inflammatory bowel disease networks switching from originator to biosimilar infliximab. Prospective clinical data were collected for 33 patients. Information was collected from electronic patient records, laboratory reports, and patient case notes. There were no clinically significant changes to disease activity, biomarkers, antidrug antibodies, or trough drug levels (P > 0.1) within a 12-month follow-up period; in addition, there were no significant adverse events reported. No infusion reactions were seen in the 264 infusions delivered. Switching from originator infliximab to the biosimilar (CT-P13) appears to be associated with neither an increase in infusion reactions nor significant loss of effectiveness in the short term.
B
iologic therapies have offered a change in the natural course and management of a number of immune-mediated inflammatory diseases. In inflammatory bowel disease (IBD), infliximab has marked efficacy in modifying disease progression and inducing remission (1, 2) . This has led to widespread adoption despite initial significant cost. In paediatric IBD (PIBD), infliximab use is increasingly employed in chronically active luminal and perianal Crohn's disease (CD) plus acute severe and chronically active colitis. The expiration of the infliximab patent and the subsequent introduction of biosimilar alternatives offer the potential to reduce financial burden and widen access to these treatments both for those commencing therapy and established patients (3) . The European Medicines Agency authorized biosimilar infliximab (CT-P13) under brand names Inflectra and Remsima in 2013 for all relevant indications. This European Medicines Agency authorization was only granted after an extensive number of experimental and preclinical studies (through a tightly regulated process) confirmed that biosimilarity truly existed between the products allowing for smaller than normal post regulatory clinical studies to reinforce this premise.
Following its launch in the United Kingdom for all indications in 2015, the safety, efficacy, and cost-effectiveness of biosimilar infliximab in adult IBD has now been extensively shown from real-world experiences and meta-analysis both for initiation and switching (4, 5) . Limited PIBD-specific data have shown similar safety and efficacy in the induction setting (3, 6) with only preliminary data (including abstract results) available for paediatric patients on established infliximab therapy switching from originator to biosimilar (7) (8) (9) . We now report prospective, nationwide, clinical safety, and efficacy data for patients from all 3 Scottish PIBD networks switching from originator infliximab to biosimilar infliximab.
METHODS
Patient identification and counselling for the switch was coordinated by the PIBD clinical nurse specialists in each centre. Patients who were receiving originator infliximab in 2016 or 2017 were identified and each case discussed within the wider multidisciplinary team. All patients were then provided with an ''opt out'' letter and an information sheet on biosimilar infliximab.
Prospective clinical data were collected on patients from all 3 Scottish regional services who switched from originator to biosimilar infliximab for maintenance of disease remission. Data were collected before the first dose of biosimilar and then at 6 and 12 months postswitch during the period between September 2016 and January 2018. Electronic patient records, case notes, and laboratory reports were used to collect information on disease activity scores, adverse events, and blood and faecal biomarkers. Patients were routinely given hydrocortisone 4 mg/kg (maximum dose 200 mg) before each infusion (routine practice in all centres before switching) and there was no vial sharing protocol in place.
Where possible, infliximab trough drug levels and antibody status was also taken and assessed before the first biosimilar infusion. An adequate trough level was deemed to be in the range of 3 to 7 mg/L and the length of infusion time (either 1 or 2 hours) remained unchanged. Clinical disease activity indices, namely the weighted Paediatric Crohn Disease Activity Index (10) and Paediatric Ulcerative Colitis Activity Index (11) were used to document disease activity at the time points stated above. Where these were not available a physicians global assessment was performed. Values for erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), albumin, faecal calprotectin, infliximab trough level, and antibody status were also collected for analysis. Data were collected before switch (0 months), at around 6 months follow-up and at around 12 months follow-up. Data for CRP, calprotectin, and trough levels were limited to laboratory-reported minimum and maximum values in each centre (CRP, <1 or <4 mg/L, calprotectin >1800 mg/L; and trough level, <0.8 mg/L). All drug levels and antibodies were performed in Exeter (https://www.exeterlaboratory.com/test/infliximab-drug-levels/) using a commercial ELISA kit (Immunodiagnostiks, Bensheim, Germany).
Statistics were calculated using Microsoft excel and SPSS software. P values were limited to patients who had data collected at all 3 time points. Where median values are quoted, range is given as an interquartile range (IQR). Specific ethical approval was not required for this review of clinical practice.
RESULTS
In total there were 39 patients prescribed originator infliximab, which represented all paediatric patients in Scotland during that time period, of which 33 patients were switched to biosimilar infliximab ( Fig. 1 ). Of the 6 who did not switch, 1 patient was deemed ineligible on medical grounds, 1 transitioned, 2 had planned discontinuation of infliximab, and 2 refused switch.
Of the 33 patients included, 16 (48%) were girls, 26 with CD, 4 with ulcerative colitis, and 3 with IBD unclassified. The median age at diagnosis (IQR) was 11.8 years (9.6, 13.4) and 13.7 years (10.1, 14.75) at the time of initially commencing anti-TNF. Twentyfive (76%) patients were prescribed coimmunosuppression with azathioprine (n ¼ 20) and methotrexate (n ¼ 5). No patients were receiving steroid therapy at the time of switching.
The median time on infliximab before switching was 1.6 years (IQR 1.5, 2.1). At the time of switching 25 patients (76%) were classified as remission and 8 had active disease (5 mild, 2 moderate, 1 severe). By 6 months, 25 of 31 (87%) patients remained in remission; 24 of 29 (83%) were in remission at 12 months.
There were no clinically significant changes in biochemical markers (P > 0.1) in the 12-month postswitch period ( Table 1 ). The median infliximab trough level at baseline was 2.9 mg/L (1.8, 5.4); at 12 months this was 4.4 mg/L (2.9, 7.5). Dose escalation, however, was performed for 16 patients during the follow-up period. Six patients had been escalated before switching and remained on this dose throughout follow-up. In patients who had antibody levels checked at all 3 time points, there was no significant change in antibody status. No acute infusion reactions were recorded within the total of 264 infusions delivered.
Only 2 patients did not complete the full 6 months follow-up postswitch. One changed to adalimumab therapy 5 months postswitch due to pharmacodynamic secondary loss of response (with adequate infliximab drug levels) and the other patient transitioned to adult services 3 months postswitch and thus further data collection was not possible. Infliximab was electively withdrawn from 2 patients due to complete remission at 9 months postchange to biosimilar; therefore, their data were missing at 12-month follow-up.
We estimate that the cost saving for this switch from originator to biosimilar over this time period was £66,000 (s75,900), based on the assumptions we made in our previous publication on this subject (3). We estimate an approximate saving of £1500 per patient per year as a result of switching.
DISCUSSION
There is established evidence to show that the use of biosimilar infliximab (CT-P13) in IBD is both safe and effective in the induction setting in patients who are anti-TNF naïve (7-9). Evidence in the maintenance of remission setting in paediatrics is far more limited, yet initial results are promising and are added to by the data in this study. The significant cost savings from using biosimilar infliximab has been documented previously and are reinforced in this current manuscript (3) . As further data emerge supporting switching, biosimilar use will continue to increase and further cost savings result.
Our current data are consistent with the published Polish and South Korean studies of similar sized paediatric populations (7,9) (n ¼ 39 and n ¼ 38, respectively), none of which showed any significant changes in disease activity or biochemical markers postswitch. The rate of remission 12 months after switching is comparable to our rate of 84% (80% [patients with CD only] and 78.9%) with only 1 infusion reaction reported from all 3 articles. Furthermore with theoretical concerns about immunogenicity not borne out by any of these studies and the fact we showed no change to antibody status postswitch this should give clinical teams confidence in undertaking switching now for their patients. More detailed studies are, however, now required to look at longer-term outcomes including secondary loss of response, drug trough levels/ antibody status, and safety. In addition, switching studies in populations in which infliximab monotherapy predominates are also needed given our own practice of predosing with steroids plus most patients being on coimmunosuppression given the possibility that immunogenicity would be at least theoretically be increased in this clinical scenario. The possible role of multiple switching between different infliximab biosimilars has not yet been investigated in paediatric populations but would also warrant further investigation.
Our analysis was supported by collection of follow-up data for the majority of patients, but there were incomplete data in some patients. Practically this was a consequence of the high remission rate of patients; thus, biomarkers were not always clinically indicated at these specific time points and patients leaving the service, switching treatments, or electively stopping treatment during the follow-up period.
The European Crohn and Colitis Organisation position statement has emphasized the importance of clear communication with patients regarding biosimilars, and has recommended that patient preference must be taken into account (12) reinforced by an American study, which has demonstrated gaps in patient knowledge about biosimilars highlighting the importance of appropriate patient education programmes (13) . In this study discussion focused on counselling and support for the parents who were anxious about the switch backed up by written information (pharmaceutical information and a letter explaining the switch process). The families were given time to review this documentation and were then seen again by the PIBD nurse specialist for any other questions immediately before their first biosimilar infusion. This was one of the most time-consuming and labour intensive parts of the switch process; however, as the majority (94%) of patients agreed for the switch to occur, it was clearly effective. After the switch, the PIBD nurse specialists who were nurse prescribers then carried out all prescription changes in addition to co-ordinating therapeutic drug monitoring at the appropriate juncture. The European Society for Paediatric Gastroenterology Hepatology and Nutrition Porto group position paper stated that caution was advised with regard to switching; however, with the publication of our data along with other supportive literature, this advice seems outdated and the authors suggest this be revised (14) .
In summary, switching from originator infliximab to the biosimilar appears not to be associated with any increase in infusion reactions or significant loss of effectiveness in the short term in PIBD and is acceptable for the patients.
